In the STING modification of epigenetic changes in squamous cell carcinoma, KDM4A inhibition activates immune responses to squamous cell carcinoma and enhances the therapeutic potential of anti-PD-1 antibody treatment for squamous cell carcinoma. The gene discussed is KDM4A; the disease is squamous cell carcinoma.